|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TMEM161B-AS1 |
Gene summary for TMEM161B-AS1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TMEM161B-AS1 | Gene ID | 100505894 |
| Gene name | TMEM161B divergent transcript | |
| Gene Alias | TMEM161B-AS1 | |
| Cytomap | 5q14.3 | |
| Gene Type | ncRNA | GO ID | NA | UniProtAcc | NA |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 100505894 | TMEM161B-AS1 | CCI_1 | Human | Cervix | CC | 6.02e-05 | 3.14e-01 | 0.528 |
| 100505894 | TMEM161B-AS1 | CCI_2 | Human | Cervix | CC | 2.27e-22 | 1.21e+00 | 0.5249 |
| 100505894 | TMEM161B-AS1 | CCI_3 | Human | Cervix | CC | 5.69e-25 | 9.27e-01 | 0.516 |
| 100505894 | TMEM161B-AS1 | H2 | Human | Cervix | HSIL_HPV | 1.49e-13 | 2.74e-01 | 0.0632 |
| 100505894 | TMEM161B-AS1 | T1 | Human | Cervix | CC | 2.49e-13 | 3.01e-01 | 0.0918 |
| 100505894 | TMEM161B-AS1 | T2 | Human | Cervix | CC | 1.77e-05 | 2.36e-01 | 0.0709 |
| 100505894 | TMEM161B-AS1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 3.27e-20 | -6.59e-01 | 0.0155 |
| 100505894 | TMEM161B-AS1 | HTA11_2487_2000001011 | Human | Colorectum | SER | 4.37e-03 | -4.65e-01 | -0.1808 |
| 100505894 | TMEM161B-AS1 | HTA11_2951_2000001011 | Human | Colorectum | AD | 3.92e-02 | -6.89e-01 | 0.0216 |
| 100505894 | TMEM161B-AS1 | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.32e-07 | -6.23e-01 | -0.1207 |
| 100505894 | TMEM161B-AS1 | HTA11_696_2000001011 | Human | Colorectum | AD | 8.08e-12 | -4.77e-01 | -0.1464 |
| 100505894 | TMEM161B-AS1 | HTA11_866_2000001011 | Human | Colorectum | AD | 2.82e-05 | -3.80e-01 | -0.1001 |
| 100505894 | TMEM161B-AS1 | HTA11_1391_2000001011 | Human | Colorectum | AD | 7.22e-14 | -6.20e-01 | -0.059 |
| 100505894 | TMEM161B-AS1 | HTA11_7862_2000001011 | Human | Colorectum | AD | 9.99e-04 | -6.15e-01 | -0.0179 |
| 100505894 | TMEM161B-AS1 | HTA11_866_3004761011 | Human | Colorectum | AD | 1.19e-19 | -6.81e-01 | 0.096 |
| 100505894 | TMEM161B-AS1 | HTA11_8622_2000001021 | Human | Colorectum | SER | 3.24e-03 | -6.39e-01 | 0.0528 |
| 100505894 | TMEM161B-AS1 | HTA11_10711_2000001011 | Human | Colorectum | AD | 4.50e-06 | -5.64e-01 | 0.0338 |
| 100505894 | TMEM161B-AS1 | HTA11_7696_3000711011 | Human | Colorectum | AD | 2.97e-19 | -5.83e-01 | 0.0674 |
| 100505894 | TMEM161B-AS1 | HTA11_6818_2000001021 | Human | Colorectum | AD | 2.11e-03 | -4.57e-01 | 0.0588 |
| 100505894 | TMEM161B-AS1 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.12e-08 | -4.30e-01 | 0.294 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |